Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Oncology Reports
Erschienen in: Current Oncology Reports 6/2016

01.06.2016 | Melanoma (RJ Sullivan, Section Editor)

Cell Cycle Regulation and Melanoma

verfasst von: Wen Xu, Grant McArthur

Erschienen in: Current Oncology Reports | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Abstract

Dysregulation of cell cycle control is a hallmark of melanomagenesis. Agents targeting the G1-S and G2-M checkpoints, as well as direct anti-mitotic agents, have all shown promising preclinical activity in melanoma. However, in vivo, standalone single agents targeting cell cycle regulation have only demonstrated modest efficacy in unselected patients. The advent of specific CDK 4/6 inhibitors targeting the G1-S transition, with an improved therapeutic index, is a significant step forward. Potential synergy exists with the combination of CDK4/6 inhibitors with existing therapies targeting the MAPK pathway, particularly in subsets of metastatic melanomas such as NRAS and BRAF mutants. This reviews summaries of the latest developments in both preclinical and clinical data with cell cycle-targeted therapies in melanoma.
Literatur
1.
2.
3.
Hunt T. Nobel lecture. Protein synthesis, proteolysis, and cell cycle transitions. Biosci Rep. 2002;22(5-6):465–86.CrossRefPubMed
4.
Nurse PM. Nobel lecture. Cyclin dependent kinases and cell cycle control. Biosci Rep. 2002;22(5-6):487–99.CrossRefPubMed
5.
6.
Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009;9(3):153–66.CrossRefPubMed
7.••
Asghar U, Witkiewicz AK, Turner NC, Knudsen ES. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov. 2015;14(2):130–46. Excellent overview of the history, biology, evolution and development of targeting CDK in oncology.CrossRefPubMedPubMedCentral
8.
Vesely J, Havlicek L, Strnad M, et al. Inhibition of cyclin-dependent kinases by purine analogues. Eur J Biochem. 1994;224(2):771–86.CrossRefPubMed
9.
De Azevedo WF, Leclerc S, Meijer L, Havlicek L, Strnad M, Kim SH. Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. Eur J Biochem. 1997;243(1-2):518–26.CrossRefPubMed
10.
Benson C, White J, De Bono J, et al. A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer. 2007;96(1):29–37.CrossRefPubMedPubMedCentral
11.
Le Tourneau C, Faivre S, Laurence V, et al. Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies. Eur J Cancer. 2010;46(18):3243–50.CrossRefPubMed
12.
Lee B, McArthur G. CDK4 inhibitors as an emerging strategy for the treatment of melanoma. Melanoma Manag Future Medicine. 2015;2(3):255–66.CrossRef
13.
14.
15.
Burdette-Radoux S, Tozer RG, Lohmann RC, et al. Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma. Invest New Drugs. 2004;22(3):315–22.CrossRefPubMed
16.
Vermeulen K, Van Bockstaele DR, Berneman ZN. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif. 2003;36(3):131–49.CrossRefPubMed
17.
Li Y, Nichols MA, Shay JW, Xiong Y. Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb. Cancer Res. 1994;54(23):6078–82.PubMed
18.
Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353(20):2135–47.CrossRefPubMed
19.
Sheppard KE, McArthur GA. The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma. Clin Cancer Res. 2013;19(19):5320–8.CrossRefPubMed
20.
Walker GJ, Flores JF, Glendening JM, Lin AH, Markl ID, Fountain JW. Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets. Genes Chromosomes Cancer. 1998;22(2):157–63.CrossRefPubMed
21.•
Young RJ, Waldeck K, Martin C, et al. Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines. Pigment Cell Melanoma Res. 2014;27(4):590–600. Identifies loss of CDKN2A expression or loss of p16INK4A as a marker of sensitivity, and loss of RB1 as a marker of resistance to CDK4 inhibition in melanoma.CrossRefPubMed
22.•
Griewank KG, Scolyer RA, Thompson JF, Flaherty KT, Schadendorf D, Murali R. Genetic alterations and personalized medicine in melanoma: progress and future prospects. J Natl Cancer Inst. 2014;106(2):djt435. Overviews the key genetic alterations in melanoma and outlines the potential future role of next generation sequencing in personalised management of melanoma.CrossRefPubMed
23.
Eliason MJ, Larson AA, Florell SR, et al. Population-based prevalence of CDKN2A mutations in Utah melanoma families. J Invest Dermatol. 2006;126(3):660–6.CrossRefPubMed
24.
Goldstein AM, Chan M, Harland M, et al. Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet. 2007;44(2):99–106.CrossRefPubMedPubMedCentral
25.
Zuo L, Weger J, Yang Q, et al. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet. 1996;12(1):97–9.CrossRefPubMed
26.
Sanki A, Li W, Colman M, Karim RZ, Thompson JF, Scolyer RA. Reduced expression of p16 and p27 is correlated with tumour progression in cutaneous melanoma. Pathology. 2007;39(6):551–7.CrossRefPubMed
27.
Karim RZ, Li W, Sanki A, et al. Reduced p16 and increased cyclin D1 and pRb expression are correlated with progression in cutaneous melanocytic tumors. Int J Surg Pathol. 2009;17(5):361–7.CrossRefPubMed
28.
Shain AH, Yeh I, Kovalyshyn I, et al. The genetic evolution of melanoma from precursor lesions. N Engl J Med. 2015;373(20):1926–36.CrossRefPubMed
29.
Fung C, Pupo GM, Scolyer RA, Kefford RF, Rizos H. p16(INK) (4a) deficiency promotes DNA hyper-replication and genetic instability in melanocytes. Pigment Cell Melanoma Res. 2013;26(2):236–46.CrossRefPubMed
30.•
Lee B, Sandhu S, McArthur G. Cell cycle control as a promising target in melanoma. Curr Opin Oncol. 2015;27(2):141–50. Comprehensive overview of the clinical data in targeting CDK, checkpoint kinases and p53 reactivation compounds in melanoma.CrossRefPubMed
31.
Flaherty KT, Lorusso PM, Demichele A, et al. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Cancer Res. 2012;18(2):568–76.CrossRefPubMed
32.
Schwartz GK, LoRusso PM, Dickson MA, et al. Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1). Br J Cancer. 2011;104(12):1862–8.CrossRefPubMedPubMedCentral
33.
34.
Infante JR, Shapiro G, Witteveen P. A Phase I study of the single-agent CDK4/6 inhibitor LEE011 in patients with advanced solid tumors and lymphomas. American Society of Clinical Oncology (ASCO) Annual Meeting 2014 Chicago, IL, USA, 30 May-3 June 2014 2014.
35.
Sanchez-Martinez C, Gelbert LM, Shannon H, et al. LY2835219, a potent oral inhibitor of the cyclin-dependent kinases 4 and 6 (CDK4/6) that crosses the blood-brain barrier and demonstrates in vivo activity against intracranial human brain tumor xenografts. Abstract B234, Mol Canc Therapeut. 2011;10(11 Suppl):B234-B.CrossRef
36.
Raub T, Gelbert LM, Wishart GN, et al. Abemaciclib (LY2835219) is an oral inhibitor of the cyclin-dependent kinases 4/6 that crosses the blood-brain barrier and demonstrates in vivo activity against intracranial human brain tumor xenografts. Drug Metab Dispos. 2015.
37.
Shapiro G, Rosen L, Tolcher A. al. e. A first in human Phase I study of the CDK4/6 inhibitor, LY2835219, for patients with advanced cancer. ASCO Annual Meeting, Chicago, IL, USA 2013; Abstract 2500.
38.
Dean JL, McClendon AK, Hickey TE, et al. Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors. Cell Cycle. 2012;11(14):2756–61.CrossRefPubMedPubMedCentral
39.
Dean JL, Thangavel C, McClendon AK, Reed CA, Knudsen ES. Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure. Oncogene. 2010;29(28):4018–32.CrossRefPubMed
40.
Konecny GE, Winterhoff B, Kolarova T, et al. Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer. Clin Cancer Res. 2011;17(6):1591–602.CrossRefPubMedPubMedCentral
41.
Logan JE, Mostofizadeh N, Desai AJ, et al. PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity. Anticancer Res. 2013;33(8):2997–3004.PubMed
42.
Michaud K, Solomon DA, Oermann E, et al. Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. Cancer Res. 2010;70(8):3228–38.CrossRefPubMedPubMedCentral
43.
Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16(1):25–35.CrossRefPubMed
44.•
Nathanson KL, Martin AM, Wubbenhorst B, et al. Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436). Clin Cancer Res. 2013;19(17):4868–78. Identifies that copy number alterations in CDKN2A and CCND1 correlate with shortening duration of disease control with Dabrafenib in treatment of BRAF-mutant melanoma.CrossRefPubMedPubMedCentral
45.
Smalley KS, Lioni M, Dalla Palma M, et al. Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol Cancer Ther. 2008;7(9):2876–83.CrossRefPubMedPubMedCentral
46.
Xing F, Persaud Y, Pratilas CA, et al. Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF. Oncogene. 2012;31(4):446–57.CrossRefPubMedPubMedCentral
47.
Yadav V, Burke TF, Huber L, et al. The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation. Mol Cancer Ther. 2014;13(10):2253–63.CrossRefPubMed
48.
49.•
Taylor M, Sosman JA, Gonzalez R, Carlino M, Postow M, al. e. Phase Ib/Ii Study Of LEE011 (Cdk4/6 Inhibitor) And LGX818 (Braf Inhibitor) In Braf-Mutant Melanoma. ESMO 2014, Marid Spain Annals of Oncology 2014; 25 (suppl 4). Preliminary Phase I results from the combination of a CDK4/6 inhibitor and BRAF inhibitor showing promising efficacy and tolerable toxicities.
50.
51.
52.
Jakob JA, Bassett Jr RL, Ng CS, et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer. 2012;118(16):4014–23.CrossRefPubMedPubMedCentral
53.••
van Herpen C, Agarwala SS, Hauschild A, al. e. Overall survival and biomarker results from a phase 2 study of mek1/2 inhibitor binimetinib (mek162) in patients with advanced nras-mutant melanoma. Annals of Oncology 2014; 25 (suppl 4). Updated data from an ongoing Phase Ib/II study showing promising response and disease control rates in the combination of a CDK4/6 inhibitor with a MEK inhibitor in NRAS mutant metastatic melanoma
54.
Kwong LN, Costello JC, Liu H, et al. Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat Med. 2012;18(10):1503–10.CrossRefPubMedPubMedCentral
55.
56.
van Herpen C, Postow M, Carlino M, al. e. A Phase 1b/2 Study of Ribociclib (LEE011; CDK4/6 inhibitor) in Combination With Binimetinib (MEK162; MEK inhibitor) in Patients With NRAS‐Mutant Melanoma. European Cancer Conference, Vienna Austria 2015.
57.
Sullivan RJ, Amaria R, Lawrence D et al. Phase 1b dose-escalation study of trametinib (MEKi) plus palbociclib (CDK4/6i) in patients with advanced solid tumors. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Nov 5-9 2015; (Boston, Massachusetts, USA).
58.
McClendon AK, Dean JL, Rivadeneira DB, et al. CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy. Cell Cycle. 2012;11(14):2747–55.CrossRefPubMedPubMedCentral
59.
Roberts PJ, Bisi JE, Strum JC, et al. Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy. J Natl Cancer Inst. 2012;104(6):476–87.CrossRefPubMedPubMedCentral
60.
Thompson R, Eastman A. The cancer therapeutic potential of Chk1 inhibitors: how mechanistic studies impact on clinical trial design. Br J Clin Pharmacol. 2013;76(3):358–69.CrossRefPubMedPubMedCentral
61.
Santamaria D, Barriere C, Cerqueira A, et al. Cdk1 is sufficient to drive the mammalian cell cycle. Nature. 2007;448(7155):811–5.CrossRefPubMed
62.
Vassilev LT, Tovar C, Chen S, et al. Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1. Proc Natl Acad Sci U S A. 2006;103(28):10660–5.CrossRefPubMedPubMedCentral
63.
Lainchbury M, Collins I. Checkpoint kinase inhibitors: a patent review (2009-2010). Expert Opin Ther Pat. 2011;21(8):1191–210.CrossRefPubMed
64.
Brooks K, Oakes V, Edwards B, et al. A potent Chk1 inhibitor is selectively cytotoxic in melanomas with high levels of replicative stress. Oncogene. 2013;32(6):788–96.CrossRefPubMed
65.
Perez RP, Lewis LD, Beelen AP, et al. Modulation of cell cycle progression in human tumors: a pharmacokinetic and tumor molecular pharmacodynamic study of cisplatin plus the Chk1 inhibitor UCN-01 (NSC 638850). Clin Cancer Res. 2006;12(23):7079–85.CrossRefPubMed
66.
Sausville E, Lorusso P, Carducci M, et al. Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors. Cancer Chemother Pharmacol. 2014;73(3):539–49.CrossRefPubMedPubMedCentral
67.
Sakurikar N, Eastman A. Will targeting Chk1 have a role in the future of cancer therapy? J Clin Oncol. 2015;33(9):1075–7.CrossRefPubMed
68.•
Daud AI, Ashworth MT, Strosberg J, et al. Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors. J Clin Oncol. 2015;33(9):1060–6. Phase 1 study evaluating a Chk1 inhibitor (MK-8776) as monotherapy and in combination with Gemcitabine, showing acceptable toxicity and promising early efficacy in melanoma.CrossRefPubMed
69.
Lindqvist A, Rodriguez-Bravo V, Medema RH. The decision to enter mitosis: feedback and redundancy in the mitotic entry network. J Cell Biol. 2009;185(2):193–202.CrossRefPubMedPubMedCentral
70.
Magnussen GI, Holm R, Emilsen E, Rosnes AK, Slipicevic A, Florenes VA. High expression of Wee1 is associated with poor disease-free survival in malignant melanoma: potential for targeted therapy. PLoS One. 2012;7(6):e38254.CrossRefPubMedPubMedCentral
71.
72.
Do K, Wilsker D, Ji J, et al. Phase I study of single-agent AZD1775 (MK-1775), a Wee1 kinase inhibitor, in patients with refractory solid tumors. J Clin Oncol. 2015;33(30):3409–15.CrossRefPubMed
73.
Carrassa L, Chila R, Lupi M, et al. Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo. Cell Cycle. 2012;11(13):2507–17.CrossRefPubMed
74.
Davies KD, Cable PL, Garrus JE, et al. Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation. Cancer Biol Ther. 2011;12(9):788–96.CrossRefPubMed
75.•
Magnussen GI, Emilsen E, Giller Fleten K, et al. Combined inhibition of the cell cycle related proteins Wee1 and Chk1/2 induces synergistic anti-cancer effect in melanoma. BMC Cancer. 2015;15:462. Demonstrated pre-clinical anti-tumour synergy in targeting the G2/M checkpoint using combined inhibition of Chk1/2 and WEE1.CrossRefPubMedPubMedCentral
76.
Reinhardt HC, Yaffe MB. Phospho-Ser/Thr-binding domains: navigating the cell cycle and DNA damage response. Nat Rev Mol Cell Biol. 2013;14(9):563–80.CrossRefPubMed
77.•
Dietlein F, Kalb B, Jokic M, et al. A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer. Cell. 2015;162(1):146–59. Demonstrated impressive preclinical efficacy with dual G2/M checkpoint kinase abrogation by targeting CHK1 and MK2 in KRAS mutant, and to a lesser extent, BRAF mutant cell lines.
78.
79.
Jackson JR, Patrick DR, Dar MM, Huang PS. Targeted anti-mitotic therapies: can we improve on tubulin agents? Nat Rev Cancer. 2007;7(2):107–17.CrossRefPubMed
80.
Kneisel L, Strebhardt K, Bernd A, Wolter M, Binder A, Kaufmann R. Expression of polo-like kinase (PLK1) in thin melanomas: a novel marker of metastatic disease. J Cutan Pathol. 2002;29(6):354–8.CrossRefPubMed
81.
de Oliveira JC, Brassesco MS, Pezuk JA, et al. In vitro PLK1 inhibition by BI 2536 decreases proliferation and induces cell-cycle arrest in melanoma cells. J Drugs Dermatol. 2012;11(5):587–92.PubMed
82.
Schmit TL, Zhong W, Setaluri V, Spiegelman VS, Ahmad N. Targeted depletion of Polo-like kinase (Plk) 1 through lentiviral shRNA or a small-molecule inhibitor causes mitotic catastrophe and induction of apoptosis in human melanoma cells. J Invest Dermatol. 2009;129(12):2843–53.CrossRefPubMedPubMedCentral
83.•
Posch C, Cholewa BD, Vujic I, et al. Combined inhibition of MEK and Plk1 has synergistic antitumor activity in NRAS mutant melanoma. J Invest Dermatol. 2015;135(10):2475–83. Demonstrated preliminary synergy with combination of a PLK1 inhibitor and a MEK inhibitor in NRAS-mutant melanoma cell lines and xenografts.CrossRefPubMedPubMedCentral
84.
Fu J, Bian M, Jiang Q, Zhang C. Roles of Aurora kinases in mitosis and tumorigenesis. Mol Cancer Res. 2007;5(1):1–10.CrossRefPubMed
85.
86.
Xie L, Meyskens Jr FL. The pan-Aurora kinase inhibitor, PHA-739358, induces apoptosis and inhibits migration in melanoma cell lines. Melanoma Res. 2013;23(2):102–13.CrossRefPubMedPubMedCentral
87.
Bonet C, Giuliano S, Ohanna M, et al. Aurora B is regulated by the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) signaling pathway and is a valuable potential target in melanoma cells. J Biol Chem. 2012;287(35):29887–98.CrossRefPubMedPubMedCentral
88.
Phadke MS, Sini P, Smalley KS. The novel ATP-competitive MEK/Aurora kinase inhibitor BI-847325 overcomes acquired BRAF inhibitor resistance through suppression of Mcl-1 and MEK expression. Mol Cancer Ther. 2015;14(6):1354–64.CrossRefPubMed
89.
Porcelli L, Guida G, Quatrale AE, et al. Aurora kinase B inhibition reduces the proliferation of metastatic melanoma cells and enhances the response to chemotherapy. J Transl Med. 2015;13:26.CrossRefPubMedPubMedCentral
90.
Komlodi-Pasztor E, Sackett DL, Fojo AT. Inhibitors targeting mitosis: tales of how great drugs against a promising target were brought down by a flawed rationale. Clin Cancer Res. 2012;18(1):51–63.CrossRefPubMed
91.
Liu Y, Hawkins OE, Su Y, et al. Targeting aurora kinases limits tumour growth through DNA damage-mediated senescence and blockade of NF-kappaB impairs this drug-induced senescence. EMBO Mol Med. 2013;5(1):149–66.CrossRefPubMedPubMedCentral
92.•
Caputo E, Miceli R, Motti ML, et al. AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment. J Transl Med. 2014;12:216. Demonstrated superior preclinical efficacy in the combination of an AurkA inhibitor with BRAF inhibitors; with MEK inhibitors and with a triple combination of all 3 drugs.
93.•
Vilgelm AE, Pawlikowski JS, Liu Y, et al. Mdm2 and aurora kinase a inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cells. Cancer Res. 2015;75(1):181–93. Demonstrated preclinical synergy in combined targeting of AURKA and MDM2 (restoring wildtype p53 function).CrossRefPubMedPubMedCentral
94.
Liu Y, Hawkins OE, Vilgelm AE, et al. Combining an aurora kinase inhibitor and a death receptor ligand/agonist antibody triggers apoptosis in melanoma cells and prevents tumor growth in preclinical mouse models. Clin Cancer Res. 2015;21(23):5338–48.CrossRefPubMed
95.
Nemunaitis JJ, Small KA, Kirschmeier P, et al. A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies. J Transl Med. 2013;11:259.CrossRefPubMedPubMedCentral
96.
97.
98.
Diab A, Martin A, Simpson L, Daud A, al. e. Phase I trial of the CDK 4/6 inhibitor, P1446A-05 (voruciclib) in combination with the BRAF inhibitor (BRAFi), vemurafenib in advanced, BRAF-mutant melanoma. 2015 ASCO ANNUAL MEETING 2015.
99.
100.
Metadaten
Titel
Cell Cycle Regulation and Melanoma
verfasst von
Wen Xu
Grant McArthur
Publikationsdatum
01.06.2016
Verlag
Springer US
Erschienen in
Current Oncology Reports / Ausgabe 6/2016
Print ISSN: 1523-3790
Elektronische ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-016-0524-y

Weitere Artikel der Ausgabe 6/2016

Current Oncology Reports 6/2016 Zur Ausgabe

Leukemia (A Aguayo, Section Editor)

Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults

Integrative Care (C Lammersfeld, Section Editor)

Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials)

Cardio-oncology (EH Yang, Section Editor)

Tyrosine Kinase Inhibitors and Vascular Toxicity: Impetus for a Classification System?

Sarcomas (SR Patel, Section Editor)

Advances in Radiation Therapy for Primary and Metastatic Adult Soft Tissue Sarcomas

Cardio-oncology (EH Yang, Section Editor)

Exercise Training in Cancer Survivors

Cardio-oncology (EH Yang, Section Editor)

Fluoropyrimidine-Induced Cardiotoxicity: Manifestations, Mechanisms, and Management

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise